Statin and cardiovascular diseases after 75 years

Statin prescription in persons older than 75 years or with frailty signs raises questions on the role of cholesterol in the genesis of atherosclerosis in this population, on the benefit of this treatment in primary or secondary prevention, and on their side effects in a context of multiple pathology...

Full description

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2016-09, Vol.37 (9), p.625-631
Main Authors: Retornaz, F, Beliard, S, Gremeaux, E, Chiche, L, Lagarde, L, Andrianasolo, M, Molines, C, Oliver, C
Format: Article
Language:fre
Subjects:
Aged
Aged, 80 and over
Atherosclerosis - blood
Atherosclerosis - prevention & control
Cardiovascular Diseases - blood
Cardiovascular Diseases - prevention & control
Cholesterol - blood
Economics and Finance
Human health and pathology
Humanities and Social Sciences
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Life Sciences
Psychiatrics and mental health
Psychology
Risk Factors
Santé publique et épidémiologie
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statin prescription in persons older than 75 years or with frailty signs raises questions on the role of cholesterol in the genesis of atherosclerosis in this population, on the benefit of this treatment in primary or secondary prevention, and on their side effects in a context of multiple pathology and multiple medications. These questions are approached with the available literature data for this population. In secondary prevention, statin prescription is recommended whatever the age although intensive treatment should be avoided. In primary prevention, in the absence of consensus, their prescription depends on both geriatric and cardiovascular risk assessment.
ISSN:0248-8663
1768-3122
DOI:10.1016/j.revmed.2016.06.001